Terkko Navigator / European Urology

Learning Curve in Robot-assisted Kidney Transplantation: Results from the European Robotic Urological Society Working Group

Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study

Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort

Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial

Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?

Randomized Trials and the Goldilocks Problem

Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9–13

Reply to Xuefeng Liu’s Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430–4: Can P

Re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430–4: Can Patient-derived Cancer Models Change the Costl

Reply to Francesco Montorsi, Paolo Capogrosso, Andrea Salonia’s Letter to the Editor re: Vincent Misrai, Enrique Rijo, Kevin C. Zorn, Nicolas Barry-Delongchamps, Aurélien Descazeaud. Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction

Re: Vincent Misrai, Enrique Rijo, Kevin C. Zorn, Nicolas Barry-Delongchamps, Aurelien Descazeaud. Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French

Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer

Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How

How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer?

What Goes Up Must Come Down: Identifying Truth from Global Prostate Cancer Epidemiology

Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index

An Opioid Prescription for Men Undergoing Minor Urologic Surgery Is Associated with an Increased Risk of New Persistent Opioid Use

Congress Calendar

Randomised Clinical Trial of Prostatic Artery Embolisation Versus a Sham Procedure for Benign Prostatic Hyperplasia

Re: Cancer Screening in the Pediatric Cancer Patient: A Focus on Genitourinary Malignancies, and Why Does a Urologist Need to Know About This?

Reply to Arnaldo Stanzione, Massimo Imbriaco, and Renato Cuocolo’s Letter to the Editor re: Marloes van der Leest, Bas Israël, Eric Bastiaan Cornel, et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer

Re: Eugene Shkolyar, Xiao Jia, Timothy C. Chang, et al. Augmented Bladder Tumor Detection Using Deep Learning. Eur Urol 2019;76:714–8

Studying Rarity in Bladder Cancer

The End of an Era: Withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European Market

Editorial Board

The Platinum Hall of Fame

Contents

Male Life Expectancy is Still Inferior to That of Women: Urologists Must Refine and Develop the Concept of Men’s Health

Augmented Bladder Tumor Detection Using Deep Learning

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer

Acknowledgement to Reviewers

Re: Urodynamics Useless in Female Stress Urinary Incontinence? Time for Some Sense—A European Expert Consensus

Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer

Re: EAU Guidelines: Prostate Cancer 2019

Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer

Re: Comparison of Population-based Observational Studies with Randomized Trials in Oncology

Re: Increased Production and Reduced Urinary Buffering of Acid in Uric Acid Stone Formers is Ameliorated by Pioglitazone

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium

Re: Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer

The Complexity of Complications: How Do We Estimate Morbidity and Target Improvements Following Radical Cystectomy?

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials

Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies

Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up

Opium Wars to the Opioid Epidemic: The Same Narcotics Cause Addiction and Kill

Re: A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment

Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group—American College of Radiology Imaging Network E2805 Trial Cohort

Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer

Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection

Re: Impact of Acute Kidney Injury and its Duration on Long-term Renal Function after Partial Nephrectomy